Shweta S. Namjoshi MD MPH

Clinical Associate Professor, Pediatrics - Gastroenterology

Bio

Dr. Namjoshi supports children and adults with intestinal failure on & off home parenteral nutrition (PN). Her research interests include equity and long term outcomes for people on home PN, iron in gastrointestinal diseases, clinical pathologic correlates in intestinal failure, IPEX, dilated enteropathy, quality of life & nutrition for patients with intestinal pseudoobstruction, and the assessment & treatment of congenital enteropathies.

Clinical Focus

Congenital onset diarrhea and enteropathy (CODEs)
Nutrition support and intestinal rehabilitation
IPEX
PLE and lymphatic diseases
GI Long Covid
Pediatric Gastroenterology

Academic Appointments

Clinical Associate Professor, Pediatrics - Gastroenterology
Member, Maternal & Child Health Research Institute (MCHRI)

Administrative Appointments

Medical Director Intestinal Rehabilitation & Nutrition Support, Lucile Packard Children's Hospital (2020 - Present)
Medical Director Children's Home Pharmacy, Lucile Packard Children's Hospital (2020 - Present)
Associate Director of Health Policy, Office of Child Health Equity, Stanford University School of Medicine (2021 - Present)

Honors & Awards

Honor Roll for Teaching Fellows, Department of Pediatrics (2023)
John Kerner MD Award for Excellence in Teaching Pediatric Gastroenterology Fellows, Division of Gastroenterology (2023)
Alwin C. Rambar-James B.D. Mark nominee, Department of Pediatrics (2022)
Learning Health System Registry Proposal Award Winner, LPCH (2022)
Auxillary Foundation Award, Children’s Books for Disability Advocacy, LPCH (2020)
Mission Zero award, Lucile Packard Children's Hospital (2020)
High Value Innovation Challenge award for Intestinal Rehabilitation Rounds, Lucile Packard Children's Hospital (2019)
UCLA Children’s Discovery and Innovation Institute Fellow’s Research Support Award, UCLA CDI (2018-2019)
NIH Fellowship Training Grant T32DK07180, NIH (2017-2019)
Housestaff Quality Improvement Award, UCLA (2014)
Resident Research Award, UCLA (2014)
Dean's Merit Scholarship, University of Southern California (2002-2006)

Boards, Advisory Committees, Professional Organizations

Committee Member, NASPGHAN Nutrition Committee (2019 - 2023)
Invited Reviewer, AGA Council, section on Short Bowel Syndrome (2022 - Present)
Committee Member, NASPGHAN Advocacy Committee (2021 - Present)
Committee Member, NASPGHAN Intestinal Rehabilitation Special Interest Group (2019 - Present)
Invited Reviewer, NASPGHAN Nutrition Section & Research Committee, Grants Review (2020 - Present)
Committee Member, Intestinal Rehabilitation & Transplantation Association Intestinal Failure Registry Committee (2021 - Present)

Professional Education

Residency: UCLA Pediatric Residency (2014) CA
Board Certification, Pediatric Gastroenterology, Hepatology, & Nutrition, American Board of Pediatrics (2019)
Fellowship: UCLA Pediatric Gastroenterology Fellowship (2019) CA
Board Certification: American Board of Pediatrics, Pediatrics (2014)
Medical Education: Penn State College of Medicine Registrar (2011) PA

Contact

Clinical (Primary)

This is the primary clinic for this clinical provider. For additional clinical locations and information, please visit the link(s) listed below in the 'Additional Clinical Info' section.

Pediatric Gastroenterology 730 Welch Rd 2nd Flr Palo Alto CA 94304 Tel: (650) 491-6686 Fax: (650) 721-3822

Additional Clinical Info

Current Research and Scholarly Interests

1. The mission of the International Intestinal Failure Registry (IIFR) is to provide the international intestinal rehabilitation and transplant community with accurate data on the outcomes and course of intestinal failure to support research, quality improvement, and policy development. https://tts.org/irta-registries/irta-ifr

2. NCT05241444 is the first-in-human, Phase 1 clinical trial will test the feasibility of the manufacturing and the safety of the administration of CD4^LVFOXP3 in up to 36 evaluable human participants with IPEX and evaluate the impact of the CD4^LVFOXP3 infusion on the disease.

3. Stanford's local Intestinal Failure Registry (SIFR) ensures ongoing assessment and improvement of intestinal failure outcomes and care provided at Stanford in collaboratiton with the Division of Pediatric Surgery. This registry focuses on clinical outcomes and social developmental outcomes for patients with short bowel syndrome, pediatric CODEs, and pseudoobstruction.

Clinical Trials

A Feasibility Study to Evaluate Safety & Benefit of Eclipse XL1 System in Adult Patients With SBS Not Recruiting
More
The Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System in Adult Patients with Short Bowel Syndrome shall enroll up to 5 Subjects at up to 2 study sites in the United States.

Stanford is currently not accepting patients for this trial. For more information, please contact SPECTRUM, .
Lead Sponsor
Stanford Investigators
- Shweta S. Namjoshi MD MPH
- Joseph (Joe) D Forrester MD MSc FAWM FACS
View full details
CD4^LVFOXP3 in Participants With IPEX Recruiting
More
This first-in-human, Phase 1 clinical trial will test the feasibility of the manufacturing and the safety of the administration of CD4^LVFOXP3 in up to 36 evaluable human participants with IPEX and evaluate the impact of the CD4^LVFOXP3 infusion on the disease.
Lead Sponsor
Stanford Investigators
View full details

2023-24 Courses

Independent Studies
- Undergraduate Directed Reading/Research
  PEDS 199 (Aut, Win)

Find a doctor

Clinics & Services

Research Resources

Professional Training